Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of drugs used to treat diabetes, have recently been associated with a rare but serious infection called Fournier gangrene.

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists ...